159 related articles for article (PubMed ID: 32809049)
21. Tumor-derived autophagosomes (DRibbles) induce B cell activation in a TLR2-MyD88 dependent manner.
Li W; Zhou M; Ren H; Hu HM; Lu L; Cao M; Wang LX
PLoS One; 2013; 8(1):e53564. PubMed ID: 23326458
[TBL] [Abstract][Full Text] [Related]
22. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
23. The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo.
Deronic A; Nilsson A; Thagesson M; Werchau D; Enell Smith K; Ellmark P
Cancer Immunol Immunother; 2021 Dec; 70(12):3629-3642. PubMed ID: 33948686
[TBL] [Abstract][Full Text] [Related]
24. HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8
Yu Z; Liu W; He Y; Sun M; Yu J; Jiao X; Han Q; Tang H; Zhang B; Xian Y; Qi J; Gong J; Xin W; Shi G; Shan F; Zhang R; Li J; Wei M
J Hematol Oncol; 2021 Apr; 14(1):71. PubMed ID: 33910591
[TBL] [Abstract][Full Text] [Related]
25. CD40-activated B cells can efficiently prime antigen-specific naïve CD8+ T cells to generate effector but not memory T cells.
Mathieu M; Cotta-Grand N; Daudelin JF; Boulet S; Lapointe R; Labrecque N
PLoS One; 2012; 7(1):e30139. PubMed ID: 22291907
[TBL] [Abstract][Full Text] [Related]
26. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
[TBL] [Abstract][Full Text] [Related]
27. Macrophages enhance tumor-derived autophagosomes (DRibbles)-induced B cells activation by TLR4/MyD88 and CD40/CD40L.
Zhou M; Li W; Wen Z; Sheng Y; Ren H; Dong H; Cao M; Hu HM; Wang LX
Exp Cell Res; 2015 Feb; 331(2):320-30. PubMed ID: 25447440
[TBL] [Abstract][Full Text] [Related]
28. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
29. Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model.
Lau SP; van Montfoort N; Kinderman P; Lukkes M; Klaase L; van Nimwegen M; van Gulijk M; Dumas J; Mustafa DAM; Lievense SLA; Groeneveldt C; Stadhouders R; Li Y; Stubbs A; Marijt KA; Vroman H; van der Burg SH; Aerts J; van Hall T; Dammeijer F; van Eijck CHJ
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690771
[TBL] [Abstract][Full Text] [Related]
30. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
[TBL] [Abstract][Full Text] [Related]
31. Breaking tolerance to tumors with dendritic cell-based immunotherapy.
Mende I; Engleman EG
Ann N Y Acad Sci; 2005 Nov; 1058():96-104. PubMed ID: 16394129
[TBL] [Abstract][Full Text] [Related]
32. Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors.
Osada T; Nagaoka K; Takahara M; Yang XY; Liu CX; Guo H; Roy Choudhury K; Hobeika A; Hartman Z; Morse MA; Lyerly HK
J Immunother; 2015 May; 38(4):155-64. PubMed ID: 25839441
[TBL] [Abstract][Full Text] [Related]
33. Irradiation Enhances Abscopal Anti-tumor Effects of Antigen-Specific Immunotherapy through Regulating Tumor Microenvironment.
Chang MC; Chen YL; Lin HW; Chiang YC; Chang CF; Hsieh SF; Chen CA; Sun WZ; Cheng WF
Mol Ther; 2018 Feb; 26(2):404-419. PubMed ID: 29248428
[TBL] [Abstract][Full Text] [Related]
34. Dendritic cell vaccination with a toll-like receptor agonist derived from mycobacteria enhances anti-tumor immunity.
Vo MC; Lee HJ; Kim JS; Hoang MD; Choi NR; Rhee JH; Lakshmanan VK; Shin SJ; Lee JJ
Oncotarget; 2015 Oct; 6(32):33781-90. PubMed ID: 26418952
[TBL] [Abstract][Full Text] [Related]
35. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
36. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
[TBL] [Abstract][Full Text] [Related]
37. Ubiquitinated proteins enriched from tumor cells by a ubiquitin binding protein Vx3(A7) as a potent cancer vaccine.
Aldarouish M; Wang H; Zhou M; Hu HM; Wang LX
J Exp Clin Cancer Res; 2015 Apr; 34(1):34. PubMed ID: 25886865
[TBL] [Abstract][Full Text] [Related]
38. IL-33 drives the antitumor effects of dendritic cells via the induction of Tc9 cells.
Liu N; Jiang Y; Chen J; Nan H; Zhao Y; Chu X; Wang A; Wang D; Qin T; Gao S; Yi Q; Yue Y; Wang S
Cell Mol Immunol; 2019 Jul; 16(7):644-651. PubMed ID: 30275536
[TBL] [Abstract][Full Text] [Related]
39. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells.
Shibolet O; Alper R; Zlotogarov L; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
Int J Cancer; 2003 Aug; 106(2):236-43. PubMed ID: 12800200
[TBL] [Abstract][Full Text] [Related]
40. CD40 and CD80/86 signaling in cDC1s mediate effective neoantigen vaccination and generation of antigen-specific CX3CR1
Yamauchi T; Hoki T; Oba T; Kajihara R; Attwood K; Cao X; Ito F
Cancer Immunol Immunother; 2022 Jan; 71(1):137-151. PubMed ID: 34037810
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
